Anti-LRRC15 Antibody Drug Conjugates
Published in World Intellectual Property Organization (WIPO) & USPTO, 2026
U.S. Patent Application Allowed. Discloses antibody-drug conjugates (ADCs) comprising anti-LRRC15 antibodies conjugated to exatecan (tubutecan platform) via a chemical linker for targeted cancer therapy.
Recommended citation: Sayumi Yamazoe, Sonia G. Tanlimco, Lore Florin, Philip M. Vitorino, Qinqin Cheng, Christine H. Tan, Yuntao Zhang, Sunitha Bachawal, Hok Yee Chan, Winse Hong Morishige, Andrew W. Drake, Deanne M. Lathers, Jaimee C. Wong. (2026). "Anti-LRRC15 Antibody Drug Conjugates." WIPO Patent Publication No. WO/2026/112472 A1 (U.S. Patent Application No. US 2026/0144884 A1; U.S. Notice of Allowance Issued).
Download Paper
